Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women-Reference-Cited by-同舟云学术

Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women

Published:2022-07-26 Issue:9 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Davenport Clare¹,Rai Nirmala²,Sharma Pawana¹,Deeks Jonathan J¹,Berhane Sarah³,Mallett Sue⁴,Saha Pratyusha⁵,Champaneria Rita⁶,Bayliss Susan E⁷,Snell Kym IE⁸,Sundar Sudha⁹

Affiliation:

1. Test Evaluation Research Group, Institute of Applied Health Research; University of Birmingham; Birmingham UK

2. School of Cancer Sciences; University of Birmingham; Birmingham UK

3. NIHR Birmingham Biomedical Research Centre; University Hospitals Birmingham NHS Foundation Trust and University of Birmingham; Birmingham UK

4. UCL Centre for Medical Imaging, Division of Medicine, Faculty of Medical Sciences; University College London; London UK

5. Medical School; University of Birmingham; Birmingham UK

6. Systematic Review Initiative; NHS Blood and Transplant; Oxford UK

7. Institute of Applied Health Research; University of Birmingham; Birmingham UK

8. Centre for Prognosis Research, School of Primary, Community and Social Care; Keele University; Keele UK

9. School of Cancer Sciences; University of Birmingham ; Birmingham UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference125 articles.

1. Combined use of ultrasound and CA125 to predict malignancy in a patient with oviduct transitional carcinoma: case report;Abdalla;BJOG: an International Journal of Obstetrics and Gynaecology,2017

2. Evaluation of HE4, CA-125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass;Al Musalhi;Oman Medical Journal,2016

3. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses;Anton;Clinics (Sao Paulo, Brazil),2012

4. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management;Bandiera;Cancer Epidemiology, Biomarkers & Prevention,2011

5. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass;Chan;Gynecologic Oncology,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative diagnostic accuracy of the IOTA SRR and LR2 scoring systems for discriminating between malignant and Benign Adnexal masses by junior physicians in Chinese patients: a retrospective observational study;BMC Women's Health;2023-11-08

2. Extracellular vesicles in gastric cancer: role of exosomal lncRNA and microRNA as diagnostic and therapeutic targets;Frontiers in Physiology;2023-08-16

3. [68Ga]Ga-FAPI-04 PET/CT in the evaluation of epithelial ovarian cancer: comparison with [18F]F-FDG PET/CT;European Journal of Nuclear Medicine and Molecular Imaging;2023-08-01

4. The ADNEX risk prediction model for ovarian cancer diagnosis: A systematic review and meta-analysis of external validation studies;2023-07-12

5. Cancer Loyalty Card Study (CLOCS): feasibility outcomes for an observational case–control study focusing on the patient interval in ovarian cancer;BMJ Open;2023-06